Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PDE8B | O95263 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47049 | 1.00 | L3MBTL1 (0.58) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL133363 | 1.00 | L3MBTL1 (0.58) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| Methylene Chloride SCHEMBL28081516 | 0.95 | POLB (0.53) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL282976 | 0.95 | POLB (0.51) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL282977 | 0.95 | POLB (0.51) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL192841 | 0.95 | POLB (0.51) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL31323435 | 0.94 | POLB (0.50) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL31048468 | 0.94 | POLB (0.50) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL20399730 | 0.94 | POLB (0.50) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL3769601 | 0.93 | HPGD (0.54) | L3MBTL1POLBHSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | claimed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| JP-3052857-A | — | — | None | — | — | JP | disclosed |
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | BRIDGE MEDICINES (US) | 2026-03-19 | — | — | US | disclosed |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-05 | — | — | US | disclosed |
| EP-4317162-B1 | 1,3-BENZODIOXOLANE-CONTAINING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | XIAN XINTONG PHARMACEUTICAL RES CO LTD (CN) | 2026-02-04 | — | — | EP | disclosed |
| WO-1994008992-A1 | HETEROCYCLIC ETHER COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION | ABBOTT LABORATORIES (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994002477-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| US-5021436-A | Antiulcer, anticoagulant, antiischaemic agent | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1991-06-04 | — | — | US | disclosed |
| US-4999362-A | Hypotensive, Antiulcer, Cytoprotective, Antithrombotic Agents | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1991-03-12 | — | — | US | disclosed |
| JP-H0352857-A | 1-SUBSTITUTED-2-(3-AMINO-1-PROPYNYL)PYRROLIDINE DERIVATIVE | AMERICAN CYANAMID CO | 1991-03-07 | — | — | JP | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2C, HTR1A, HTR2A | L3MBTL1 3206/4885POLB 3873/4885HSD17B10 960/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | L3MBTL1 4136/4885POLB 4820/4885HSD17B10 1259/4885 |
| US-20260078121-A1 | INHIBITORS OF ENL/AF9 YEATS AND FLT3 | MLLT3, MLLT1, FLT3 | L3MBTL1 170/4885POLB 4206/4885HSD17B10 2268/4885 |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | L3MBTL1 513/4885POLB 781/4885HSD17B10 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.